文献速递胸部肿瘤

MET外显子14改变肺癌的PD-L1表达、肿瘤突变负荷与免疫治疗反应

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
PubMed 文献 · Ann Oncol · 2018-01-01

本研究纳入两家学术机构147例MET外显子14改变肺癌患者,分析PD-L1表达、TMB及免疫检查点抑制剂疗效。结果显示PD-L1≥50%者占41%,中位TMB低于非选择NSCLC,客观缓解率17%,中位PFS 1.9个月,总体疗效有限。

要点

  • MET外显子14改变肺癌中PD-L1≥50%者占41%,但中位TMB低于非选择NSCLC。
  • 免疫检查点抑制剂客观缓解率17%,中位PFS仅1.9个月,总体疗效有限。
  • 缓解未富集于PD-L1≥50%或高TMB肿瘤,PD-L1与TMB无显著关联。

核心结论

  • MET外显子14改变肺癌中相当比例表达PD-L1,但中位TMB低于非选择NSCLC,免疫治疗总体临床疗效有限。

研究设计与样本

  • 研究纳入两家学术机构147例任何分期的MET外显子14改变肺癌患者,回顾临床病理和分子特征并分析免疫检查点抑制剂反应。

主要发现

  • 111例可评估肿瘤样本中PD-L1表达0%、1%-49%、≥50%分别占37%、22%、41%。
  • 队列A中位TMB 3.8 vs 5.7突变/兆碱基(P<0.001,n=78 vs 1769),队列B中位TMB 7.3 vs 11.8突变/兆碱基(P<0.001,n=62 vs 1100)。
  • PD-L1表达与TMB无关联(Spearman's rho=0.18,P=0.069)。
  • 24例可评估反应患者中客观缓解率17%(95%CI 6%至36%),中位无进展生存期1.9个月(95%CI 1.7-2.7)。
  • 缓解未在PD-L1≥50%或高TMB肿瘤中富集。

临床怎么用

  • MET外显子14改变肺癌患者免疫检查点抑制剂单药或联合治疗总体疗效有限,不应仅凭PD-L1≥50%或高TMB预测免疫治疗获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung cancers in prospective trials. In contrast, the activity of immunotherapy, PD-L1 expression and tumor mutational burden (TMB) of these tumors and are not well characterized. PATIENTS AND METHODS: Patients with MET exon 14-altered lung cancers of any stage treated at two academic institutions were identified. A review of clinicopathologic and molecular features, and an analysis of response to single-agent or combination immune checkpoint inhibition were conducted. PD-L1 immunohistochemistry was carried out and TMB was calculated by estimation from targeted next-generation sequencing panels. RESULTS: We identified 147 patients with MET exon 14-altered lung cancers. PD-L1 expression of 0%, 1%-49%, and ≥50% were 37%, 22%, and 41%, respectively, in 111 evaluable tumor samples. The median TMB of MET exon 14-altered lung cancers was lower than that of unselected non-small-cell lung cancers (NSCLCs) in both independently evaluated cohorts: 3.8 versus 5.7 mutations/megabase (P < 0.001, n = 78 versus 1769, cohort A), and 7.3 versus 11.8 mutations/megabase (P < 0.001, n = 62 versus 1100, cohort B). There was no association between PD-L1 expression and TMB (Spearman's rho=0.18, P = 0.069). In response-evaluable patients (n = 24), the objective response rate was 17% (95% CI 6% to 36%) and the median progression-free survival was 1.9 months (95% CI 1.7-2.7). Responses were not enriched in tumors with PD-L1 expression ≥50% nor high TMB. CONCLUSION: A substantial proportion of MET exon 14-altered lung cancers express PD-L1, but the median TMB is lower compared with unselected NSCLCs. Occasional responses to PD-1 blockade can be achieved, but overall clinical efficacy is modest.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018. PMID: 30165371. doi:10.1093/annonc/mdy334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。